netupitant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
neurokinin NK1 (substance P) receptor antagonist 4898 290297-26-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Ro 67-3189/000
  • netupitant
Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Delayed emesis has been largely associated with the activation of tachykinin family neurokinin 1 (NK-1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.
  • Molecular weight: 578.60
  • Formula: C30H32F6N4O
  • CLOGP: 6.76
  • LIPINSKI: 2
  • HAC: 5
  • HDO: 0
  • TPSA: 39.68
  • ALOGS: -5.31
  • ROTB: 7
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 5.54 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.83 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 34.28 hours Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 27, 2015 EMA Helsinn Birex Pharmaceuticals Ltd
Oct. 10, 2014 FDA HELSINN HLTHCARE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Subclavian artery occlusion 42.28 36.61 6 878 168 79743336
Hypomagnesaemia 39.48 36.61 16 868 46895 79696609

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000010262 Neurokinin 1 Antagonists
FDA EPC N0000175786 Substance P/Neurokinin-1 Receptor Antagonist
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:55350 neurokinin-1 receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.9 Basic
pKa2 3.35 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
300MG;EQ 0.5MG BASE AKYNZEO HELSINN HLTHCARE N205718 Oct. 10, 2014 RX CAPSULE ORAL 11559523 Nov. 18, 2030 METHOD OF TREATING EMESIS
300MG;EQ 0.5MG BASE AKYNZEO HELSINN HLTHCARE N205718 Oct. 10, 2014 RX CAPSULE ORAL 8623826 Nov. 18, 2030 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE AKYNZEO HELSINN HLTHCARE N205718 Oct. 10, 2014 RX CAPSULE ORAL 9186357 Nov. 18, 2030 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE AKYNZEO HELSINN HLTHCARE N205718 Oct. 10, 2014 RX CAPSULE ORAL 9943515 Nov. 18, 2030 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE AKYNZEO HELSINN HLTHCARE N205718 Oct. 10, 2014 RX CAPSULE ORAL 10828297 Dec. 17, 2030 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE AKYNZEO HELSINN HLTHCARE N205718 Oct. 10, 2014 RX CAPSULE ORAL 9271975 Sept. 9, 2031 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Substance-P receptor GPCR ANTAGONIST Ki 9.02 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
7732P08TIR UNII
D05152 KEGG_DRUG
4033795 VUID
N0000191094 NUI
4033795 VANDF
C1700730 UMLSCUI
CHEBI:85155 CHEBI
CHEMBL206253 ChEMBL_ID
6451149 PUBCHEM_CID
DB09048 DRUGBANK_ID
8409 INN_ID
C508854 MESH_SUPPLEMENTAL_RECORD_UI
5742 IUPHAR_LIGAND_ID
1552337 RXNORM
30612 MMSL
d08299 MMSL
015714 NDDF
716123009 SNOMEDCT_US
GAW PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AKYNZEO HUMAN PRESCRIPTION DRUG LABEL 2 69639-101 CAPSULE 300 mg ORAL NDA 26 sections
AKYNZEO HUMAN PRESCRIPTION DRUG LABEL 2 69639-101 CAPSULE 300 mg ORAL NDA 26 sections
AKYNZEO HUMAN PRESCRIPTION DRUG LABEL 2 69639-101 CAPSULE 300 mg ORAL NDA 26 sections